Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SepternaSEPN -1.77%12 Net Margin % is -32.56% as of Mar. 2026. GuruFocus rates SEPN with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Septerna ranks better than 55.72% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Septerna's Net Income for the
three
months ended in Mar. 2026 was $-8.64 Mil. Septerna's Revenue for the
three
months ended in Mar. 2026 was $26.52 Mil. Therefore, Septerna's net margin for the quarter that ended in Mar. 2026 was -32.56%.
The historical rank and industry rank for Septerna's Net Margin % or its related term are showing as below:
SEPN'
s Net Margin % Range Over the Past 10 Years
Min: -6678.88 Med: -106.37 Max: 2768.21
Current: -49.88
SEPN's Net Margin % is ranked better than 55.72% of 944
companies
in the Biotechnology industry
Industry Median: -88.09
vs SEPN: -49.88
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Septerna Net Margin % Related Terms
Septerna Net Margin % Historical Data
* Premium members only.
The historical data trend for Septerna's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Septerna's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Septerna Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Septerna's Net Margin % distribution charts can be found below:
* The bar in red indicates where Septerna's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Septerna (SEPN) has a Net Margin % of -32.56% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Septerna and its competitors. According to the industry distribution chart, Septerna ranks #418 out of 944 companies in the Biotechnology industry, placing it in the top 44.3%.
Is Septerna's Net Margin % too high?
Septerna's current Net Margin % is -32.56%. Based on the distribution chart, Septerna ranks #418 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Septerna has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Septerna's Net Margin % compare to NTLA and AVBP?
According to the Biotechnology industry distribution chart, Septerna ranks #418 out of 944 companies for Net Margin %. This puts Septerna in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Septerna and its competitors. Septerna's current Net Margin % is -32.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Septerna stock overvalued right now?
Septerna (SEPN) has a current Net Margin % of -32.56%. The current Net Margin % is -32.56%. Septerna's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Septerna (SEPN), the current Net Margin % is -32.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
12GF Score
Get the complete analysis for SEPN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEPN has been successfully added to your 
